Claim Ledger
38% answered
Did management answer the analysts?
12 analyst questions audited, 5 evaded or deflected.
View Claim Ledger →
Divi's Laboratories — Q4 FY25
Divis Laboratories reported a strong Q4 FY25 with PAT of INR 662 crore, up 23% YoY, driven by robust custom synthesis momentum and stable generic volumes despite pricing headwinds.
bullish
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Divis Laboratories reported a strong Q4 FY25 with PAT of INR 662 crore, up 23% YoY, driven by robust custom synthesis momentum and stable generic volumes despite pricing headwinds. The company signed a long-term supply agreement for an advanced intermediate, reinforcing its CDMO leadership. Management guided for double-digit revenue growth in FY26, supported by Kakinada phase I commissioning, peptide capacity expansion, and a healthy RFP pipeline. However, Red Sea disruptions continue to extend lead times by 2-3 weeks, impacting logistics costs. Key risks include persistent generic pricing pressure and potential delays in customer regulatory approvals for new contracts.
डिविस लैबोरेटरीज ने वित्त वर्ष 2025 की चौथी तिमाही में शुद्ध लाभ 662 करोड़ रुपये दर्ज किया, जो पिछले साल से 23% अधिक है। यह वृद्धि कस्टम सिंथेसिस (ग्राहकों के लिए खास रसायन बनाने का काम) में तेजी और जेनेरिक दवाओं (सस्ती दवाओं) की स्थिर बिक्री से हुई, भले ही कीमतों पर दबाव था। कंपनी ने एक उन्नत मध्यवर्ती रसायन के लिए दीर्घकालिक आपूर्ति समझौता किया, जिससे दवा निर्माण में उसकी अग्रणी भूमिका मजबूत हुई। प्रबंधन ने वित्त वर्ष 2026 में दो अंकों की आय वृद्धि का अनुमान लगाया है, जो काकीनाडा संयंत्र के शुरू होने, पेप्टाइड (प्रोटीन के छोटे टुकड़े) उत्पादन क्षमता बढ़ने और नए ऑर्डरों से मिलेगी। हालांकि, लाल सागर में व्यवधान से शिपिंग में 2-3 सप्ताह की देरी हो रही है, जिससे लागत बढ़ रही है। मुख्य जोखिमों में जेनेरिक दवाओं की कीमतों पर लगातार दबाव और नए अनुबंधों के लिए नियामक मंजूरी में देरी शामिल है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Generic pricing pressure persists
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Custom Synthesis Revenue Mix (Q4)
51%
+3pp YoY
Custom synthesis contributed 51% of Q4 revenue, up from 48% in Q4 FY24, reflecting strong CDMO momentum.
Export to Europe & US (FY25)
73%
+3pp YoY
Exports to Europe and US increased to 73% of total sales in FY25 from 70% in FY24, indicating deeper market penetration.
Kakinada Project Spend
₹1,497 Cr
N/A
Total spend on Kakinada unit reached ₹1,497 crore as of March 2025, with phase I commissioning underway.
Cash on Books
₹3,696 Cr
N/A
Cash reserves stood at ₹3,696 crore as of March 2025, providing strong balance sheet flexibility.
What Changed vs Last Quarter
NEW
Kakinada phase I completion with ₹200 crore additional spend
Phase I of Kakinada will require about ₹200 crore more in capex, with benefits expected to flow from FY26 onwards.
NEW
New CS contracts commercialization by late 2026/early 2027
The two long-term custom synthesis contracts announced are expected to start commercial production around Q3/Q4 2026 or early 2027, subject to regulatory approvals.
UPDATED
Double-digit revenue growth in FY26
Management expects overall revenue to grow at a double-digit rate in FY26, driven by custom synthesis and generics.
DROPPED
Kakinada Phase I full commissioning in 6 months
The remaining part of Phase I at Kakinada is expected to be operational in about six months.
DROPPED
Generics and custom synthesis to be 50-50%
The company aims for a balanced revenue mix of 50% generics and 50% custom synthesis over time.
NEW RISK
Customer regulatory approval delays
Commercialization of new CS contracts depends on customer regulatory approvals, which could slip beyond the guided timeline.
NEW RISK
Inventory normalization uncertainty
Inventory remains elevated at ~₹3,000 crore; management could not confirm if this level will sustain, posing working capital risk.
RISK GONE
US tariff policy changes
Potential changes in US trade policies could impact export competitiveness, though management noted no immediate tariffs on India.
RISK GONE
Kakinada ramp-up costs
Initial operational expenses at the new Kakinada facility may temporarily pressure margins until full utilization is achieved.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY25
Ongoing price erosion in generics continues to pressure revenue growth despite volume increases.
Mentioned in Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24
Phase-wise production at the 200-acre greenfield Kakinada facility will begin in December 2024, initially focusing on backward integration and regulatory qualifications.
Mentioned in Q1 FY24, Q1 FY25
While BIOSECURE Act opportunities are emerging, the timing and conversion of phase II/III molecules into commercial revenue remain uncertain and may take years.
Mentioned in Q1 FY25, Q2 FY25
Total capital expenditure for FY25, including Kakinada, is expected to be around INR 1,600 crores, with INR 1,000 crores remaining to be spent.
Mentioned in Q1 FY24, Q2 FY25
While raw material prices have stabilized, they remain sensitive to Middle East developments and crude oil fluctuations, posing a risk to margins.
Fast read
Guidance and risk preview
Management expects overall revenue to grow at a double-digit rate in FY26, driven by custom synthesis and generics.
Management acknowledged continued high competition and pricing headwinds in the generics segment, which could pressure margins.
View Risks →